Back to Search
Start Over
Diabetes mellitus and multiple myeloma; common features of two distinct entities.
- Source :
-
Diabetes/metabolism research and reviews [Diabetes Metab Res Rev] 2022 Jul; Vol. 38 (5), pp. e3535. Date of Electronic Publication: 2022 May 25. - Publication Year :
- 2022
-
Abstract
- Diabetes mellitus (DM) has attained the status of a global pandemic. Cardiovascular disease (CV) was the leading cause of morbidity in people with type 2 DM, however, a transition from CV to cancer as the leading contributor to DM related death has been observed lately. Multiple myeloma (MM) is the second most common haematological malignancy. Obesity is a common risk factor for both DM and MM. Although data are limited, studies have shown that DM might be associated with increased risk for the development of MM. The presence of DM might affect the course of patients with MM, since hyperglycemia may have an impact on both the efficacy and the adverse effects of antimyeloma therapy. In parallel, DM and MM share common clinical presentations, such as nephropathy, neuropathy, and CV. In terms of antidiabetic medications, metformin might present a synergistic effect with antimyeloma drugs and also prevent some of the adverse effects of these drugs; pioglitazone might have favourable effects when given as add on treatment in people with relapsed or refractory MM. No clinically important interactions have been observed between antidiabetic agents and the most commonly used antimyeloma drugs. Further data are needed to examine the effect of all classes of antidiabetic medication on MM and its complications. A baseline assessment of risk factors for glucose intolerance and close monitoring of glucose levels during therapy is strongly suggested for patients with MM.<br /> (© 2022 John Wiley & Sons Ltd.)
- Subjects :
- Humans
Hypoglycemic Agents adverse effects
Pioglitazone therapeutic use
Diabetes Mellitus, Type 2 chemically induced
Diabetes Mellitus, Type 2 complications
Diabetes Mellitus, Type 2 drug therapy
Metformin therapeutic use
Multiple Myeloma chemically induced
Multiple Myeloma complications
Multiple Myeloma drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1520-7560
- Volume :
- 38
- Issue :
- 5
- Database :
- MEDLINE
- Journal :
- Diabetes/metabolism research and reviews
- Publication Type :
- Academic Journal
- Accession number :
- 35555946
- Full Text :
- https://doi.org/10.1002/dmrr.3535